Press release
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentationLeiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival" is scheduled for Sunday, March 31, 2019, as part of the session "Predictive Biomarkers for Immunotherapy" (12:45-2:45pm, Marcus Auditorium- Bldg A-GWCC).
The data will outline the effects of vaccination with ISA Pharmaceuticals´ therapeutic vaccine ISA101 during chemotherapy in 77 patients with advanced, recurrent or metastatic cervical cancer in a dose assessment study.
ISA101 is directed against the HPV16 oncoproteins E6/E7 and is the Company´s clinical-stage lead compound. It is being developed to treat HPV16-induced cancers such as cervical cancer and head-and-neck cancer. Clinical efficacy of ISA101 in combination with Regeneron’s PD-1 inhibitor cemiplimab is currently being tested in a randomized controlled Phase 2 trial in platinum refractory, HPV16-positive oropharyngeal cancer patients (NCT03669718). The results to be presented at AACR form the basis for a planned Phase 3 trial, in which the clinical benefit of the combination of ISA101 plus cemiplimab on top of standard-of-care chemotherapy will be studied in patients with advanced HPV16-positive cervical cancer.
###
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP® immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases.
For more information, please visit www.isa-pharma.com.
SLP® and AMPLIVANT® are registered trademarks in Europe.
Miranda Molenaar
ISA Pharmaceuticals B.V.
J.H. Oortweg 19
NL-2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
E: info@isa-pharma.com
Contact & Media Inquiries:
akampion
Dr. Ludger Wess Ines-Regina Buth
Managing Partner Managing Partner
Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68
info(at)akampion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019 here
News-ID: 1676402 • Views: …
More Releases from ISA Pharmaceuticals
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research
Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute.
The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…

ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019.
The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening…
More Releases for ISA101
HPV16+ Cancer Pipeline Appears Robust With 10+ Key Pharma Companies Actively Wor …
DelveInsight's, "Human papillomavirus 16-positive (HPV16+) cancers Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest…
Human Papillomavirus Market Set for Breakthrough Expansion by 2034, Driven by In …
Curious about the rapid evolution of the human papillomavirus market? DelveInsight's latest 7MM report uncovers crucial epidemiological patterns, transformative market trends, and highlights leading innovators like VLP The Vaccines Company SL, Voltron Therapeutics Inc., Rubius Therapeutics, Bristol-Myers Squibb, Precigen Inc., and Privo Technologies-all shaping the future of HPV prevention and treatment.
DelveInsight's "Human Papillomavirus - Market Insight, Epidemiology, And Market Forecast - 2034′′ report offers an in-depth understanding of the human…
HPV16+ Anogenital Cancers Therapeutics Market Size in 7MM is expected to grow at …
DelveInsight's "HPV16+ Anogenital Cancers Market Insights, Epidemiology, and Market Forecast-2032" Report delivers an in-depth understanding of the HPV16+ Anogenital Cancers, historical and forecasted epidemiology as well as the HPV16+ Anogenital Cancers market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the HPV16+ Anogenital Cancers Market Share @ HPV16+ Anogenital Cancers Market Outlook- https://www.delveinsight.com/sample-request/hpv16-anogenital-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …
Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019.
The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00…
ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 p …
Leiden, The Netherlands, September 27, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2 combination trial with ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody and PD-1 checkpoint inhibitor (NCT02426892). The open-label trial in patients with HPV-16 associated cancers demonstrated safety and efficacy, resulting in an improved survival as compared to historical nivolumab monotherapy results.…